Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 15/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 15/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 15/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 15/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 15/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 13/20 | 1.00 |
| ▸ | GABRP | O00591 | 8/20 | 1.00 |
| ▸ | GABRD | O14764 | 8/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 8/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 8/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 8/20 | 1.00 |
| ▸ | GABRE | P78334 | 8/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 8/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 8/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 8/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abecarnil SCHEMBL29716465 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9425899 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8845290 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9426144 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9425751 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Abecarnil SCHEMBL4311489 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31623789 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8845900 | 0.92 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Abecarnil SCHEMBL5083743 | 0.91 | GABRA1 (0.83) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8845197 | 0.91 | GABRA1 (0.84) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025976-A | Method for differentiating hematopoietic stem/progenitor cells into granulocytes | 苏州血霁生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| CN-118786209-A | Method for differentiating hematopoietic stem/progenitor cells into NK cells | 苏州血霁生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| EP-4247386-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2023165503-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | 苏州血霁生物科技有限公司 | 2023-09-07 | — | — | WO | claimed |
| WO-2022109052-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| WO-2022086835-A1 | COMBINATION PRODUCTS TO MITIGATE THE RISK OF NON-BENZODIAZEPINE BENZODIAZEPINE AGONIST ADVERSE REACTION AND OVERDOSE | PRESTI MICHAEL (US) | 2022-04-28 | — | — | WO | claimed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| US-20180055827-A1 | TREATMENT OF AUTISM AND AUTISM SPECTRUM DISORDERS (ASD) | LABANCE SARAH E (US) | 2018-03-01 | — | — | US | claimed |
| US-20030045541-A1 | GABA-Receptor modulators with NMDA-Antagonistic activity | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-06 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| WO-2000051590-A2 | NEUROPHARMACOLOGICAL TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-09-08 | — | — | WO | claimed |
| EP-0789567-A4 | A METHOD FOR TREATING VASCULAR HEADACHES | GEN HOSPITAL CORP (US) | 1999-01-13 | — | — | EP | claimed |
| US-5767117-A | BINDING OF AN AGONIST TO A 4-AMINOBUTYRIC ACID RECEPTOR AT THE BENZODIAZEPINE SITE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-06-16 | — | — | US | claimed |
| US-5700808-A | TREATING SLEEP DISTURBANCE, EPILEPSY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-23 | — | — | US | claimed |
| EP-0789567-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1997-08-20 | — | — | EP | claimed |
| WO-1996015782-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| US-5414002-A | Anxiolytic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-05-09 | — | — | US | claimed |
| EP-0239667-B1 | 5-OR 6-SUBSTITUTED BETA-CARBOLINE-3-CARBOXYLIC-ACID ESTERS | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045541-A1 | GABA-Receptor modulators with NMDA-Antagonistic activity | GRIN2A, GRIN1, GABRD | GABRA1 4/4885GABRG2 19/4885GABRB3 16/4885 |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRA1 8/4885GABRG2 14/4885GABRB3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.